In recent developments within the field of ophthalmology, Zhongmou Therapeutics Technology (Wuhan) Co., Ltd., has released clinical data for its optogenetic gene therapy aimed at treating Retinitis Pigmentosa (RP), a prevalent form of inherited retinal disease (IRD). This update represents a significant contribution to the ongoing research into IRDs, which result from genetic defects in the retina that lead to the degradation and eventual death of photoreceptor cells, culminating in total vision loss.
Retinitis Pigmentosa impacts over 400,000 individuals in the domestic population and more than 2 million individuals worldwide. Zhongmou Therapeutics’s optogenetic gene therapy, known as ZM-02, has demonstrated significant improvement in the visual capabilities of patients severely affected by RP, including better minimum light sensitivity and overall visual performance in various simulated light conditions. These results indicate the therapy’s potential effectiveness for individuals with this degenerative condition.
The effectiveness of ZM-02 is notable for its improvement in patients’ ability to recognize letters from a state of near-total blindness. Importantly, the therapy’s applicability is not restricted by the specific genetic mutations causing RP, suggesting its potential as a universal gene therapy solution.
The approach utilized by Zhongmou Therapeutics, with support from PackGene for the provision of Adeno-Associated Virus (AAV) vectors, introduces light-sensitive proteins into the remaining non-photoreceptive cells in the retina. This method aims to restore the retina’s light-sensing capabilities by allowing these cells to respond to light stimuli, thus converting light signals into electrical signals for the brain to interpret.
Dr. Shen Yin, the founder of Zhongmou Therapeutics and an expert in neuro-ophthalmology and hereditary eye diseases, has highlighted the unique benefits of optogenetics in treating all forms of retinal diseases linked to photoreceptor cell malfunction. The therapy, which requires only a single treatment, has the potential for long-term benefits, significantly enhancing patients’ quality of life.
Clinical trials have supported the therapy’s promise, revealing significant improvements in visual functions among patients, such as the ability to navigate in unfamiliar environments and recognize objects under normal lighting. These advancements suggest ZM-02’s potential efficacy as a treatment for RP.
Zhongmou Therapeutics’ efforts in addressing the complexities of gene therapy development reflect a commitment to advancing treatment options for hereditary retinal diseases. Through systematic scientific research and the development of innovative treatment methodologies, Zhongmou Therapeutics is contributing to the broader goal of improving vision restoration and quality of life for individuals affected by hereditary retinal diseases.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
Plasmids GMP Services
AAV GMP Services
